The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis.
(2012) Advances in Urology — Vol. 2012, p. 612707 (2012)
Files
Schubert-2012-Theroleofadjuvanthormonal.pdf
Restricted Access - Adobe PDF
- 486.2 KB
Details
- Authors
- Abstract
- Introduction. To assess the role of adjuvant androgen deprivation therapy (ADT) in high-risk prostate cancer patients (PCa) after surgery. Materials and Methods. The analysis case matched 172 high-risk PCa patients with positive section margins or non-organ confined disease and negative lymph nodes to receive adjuvant ADT (group 1, n = 86) or no adjuvant ADT (group 2, n = 86). Results. Only 11.6% of the patients died, 2.3% PCa related. Estimated 5-10-year clinical progression-free survival was 96.9% (94.3%) for group 1 and 73.7% (67.0%) for group 2, respectively. Subgroup analysis identified men with T2/T3a tumors at low-risk and T3b margins positive disease at higher risk for progression. Conclusion. Patients with T2/T3a tumors are at low-risk for metastatic disease and cancer-related death and do not need adjuvant ADT. We identified men with T3b margin positive disease at highest risk for clinical progression. These patients benefit from immediate adjuvant ADT.
- Affiliations
Citations
Schubert, M., Joniau, S., Gontero, P., Kneitz, S., Scholz, C.-J., Kneitz, B., Briganti, A., Karnes, R. J., Tombal, B., Walz, J., Hsu, C.-Y., Marchioro, G., Bader, P., Bangma, C., Frohneberg, D., Graefen, M., Schröder, F., Van Cangh, P., van Poppel, H., & Spahn, M. (2012). The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis. Advances in Urology, 2012, 612707. https://doi.org/10.1155/2012/612707 (Original work published 2012)